Eurofins Scientific Shares Drop 1.5%, Facing Resistance at €71.10
The Luxembourg-based bioanalytical testing specialist loses ground in the Paris session, moving against a slightly bullish CAC 40. The decline occurs as Jefferies raises its price target while maintaining a negative outlook on the stock.
The Stock Drops 1.74%, Among the Most Notable Declines in the CAC 40
Eurofins Scientific shares fell 1.74% to €69.86, down from €71.10 the previous day, in a CAC 40 that is up 0.18% at 8,355 points. The stock is among the most significant declines in the index this morning, alongside Capgemini and Dassault Systèmes. Despite this drop, the stock still shows a gain of 11.74% over the month and 13.85% over the year, driven by the rise observed since the low in April, after the rebound on July 9. The RSI reaches 70, on the border of the overbought zone, which makes a pause coherent after several sessions of gains. However, the price remains above its three moving averages: the MM20 at €68.71 (a gap of 1.67%), the MM50 at €64.95, and the MM200 at €63.80, providing a cushion of nearly 9.5% on the latter. The resistance at €71.10, which corresponds to the previous day's price, has not been breached.
Jefferies Raises Target from €48 to €60 but Maintains Underperform Rating
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This Tuesday, Jefferies raised its price target on Eurofins Scientific from €48 to €60, while maintaining an underperform rating. Based on the current price of €69.86, the new target from the American broker remains about 14% lower. This measured message echoes that already expressed at the end of June by another major broker, who had reiterated a cautious view on the stock. The fundamental context remains marked by the Q1 2026 publication at the end of April, deemed disappointing in terms of organic growth but supported by margins. The next financial milestone will be the publication of the half-year results. The stock continues to trade well above its long-term moving averages, against the backdrop of a catch-up that began in the spring.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.